# Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)

> **NCT04568616** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 178 (actual)

## Conditions studied

- Breast Cancer
- ER Positive Breast Cancer

## Interventions

- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT04568616
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-13
- **Primary completion:** 2025-04-02
- **Final completion:** 2029-08-13
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04568616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04568616, "Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04568616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*